Hepatic Encephalopathy Management

Initial Treatment

• Lactulose should be initiated immediately as first-line treatment for patients with hepatic encephalopathy who have not improved with IV fluids, with a goal of achieving 2-3 soft stools per day, as recommended by the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) 1, 2, 3, 4, 5, 6
• The initial dosing of lactulose is 30-45 mL every 1-2 hours until 2 bowel movements occur, and maintenance dosing is 25-30 mL (20-30 g) orally every 12 hours, with a strength of evidence of GRADE II-1, B, 1 6, 3, 4, 5, 1
• For patients who cannot take oral medications, lactulose can be administered via nasogastric tube, as recommended by the Clinical and Molecular Hepatology society 6

Medication Management

• Rifaximin can be added to lactulose, with a dosage of 550 mg orally twice daily, and has been shown to be particularly effective in combination with lactulose, with better recovery rates and shorter hospital stays, as recommended by the Clinical and Molecular Hepatology society, AASLD, and EASL, with a strength of evidence of GRADE I, A, 1 6, 3, 4, 1
• L-ornithine L-aspartate (LOLA) can be administered intravenously at 30 g/day and can lower the grade of hepatic encephalopathy faster and shorten the duration until symptom recovery, as recommended by the Clinical and Molecular Hepatology society, with a strength of evidence of GRADE I, B, 2 6, 1
• Albumin can be considered at 1.5 g/kg/day and has shown improved recovery rates within 10 days compared to lactulose alone, as recommended by the Clinical and Molecular Hepatology society 6
• Branched-chain amino acids (BCAAs) can be supplemented orally at 0.25 g/kg/day and help inhibit proteolysis and decrease the influx of toxic materials via the blood-brain barrier, as recommended by the Clinical and Molecular Hepatology society, with a strength of evidence of GRADE I, B, 2 6, 1
• Neomycin can be used as an alternative therapy, but is limited by ototoxicity and nephrotoxicity, with a strength of evidence of GRADE II-1, B, 2 1
• Metronidazole can be used as an alternative therapy, but is limited by neurotoxicity concerns, with a strength of evidence of GRADE II-3, B, 2 1

Lifestyle Modifications

• Frequent feeding schedules with small, frequent meals (4-6 times/day including night snack) can improve nitrogen balance in patients with alcoholic cirrhosis, as recommended by the Journal of Hepatology society and AASLD and EASL 7, 6, 3
• Patients with HE should receive daily energy intake of 35-40 kcal/kg and protein intake of 1.2-1.5 g/kg, with no protein restriction, and consider vegetable and dairy protein sources for those with recurrent/persistent HE, as recommended by the AASLD and EASL 2, 6, 3
• Alcohol abstinence is critical for reducing mortality and complications, and referral to addiction specialists for treatment is recommended, as advised by the Journal of Hepatology society and AASLD and EASL 7, 3

Evaluation and Follow-up

• Large-volume paracentesis can be indicated for patients with tense ascites, followed by sodium restriction and diuretic therapy, as recommended by the Hepatology society 8
• Liver transplantation evaluation should be considered in patients with poor prognosis, indicated by the development of ascites and hepatic encephalopathy, as recommended by the Hepatology society and AASLD and EASL 8, 2, 6, 3
• Regular follow-up is necessary to monitor neurological status, adjust medications to prevent recurrence, and educate patients and caregivers about medication adherence and early signs of recurrence, as recommended by the Hepatology society, AASLD, and EASL 1, 6, 4
• Patients with grade 3-4 hepatic encephalopathy are at risk for aspiration and should be monitored closely, and patients with grade III-IV HE are at high risk for aspiration and should be admitted to the ICU immediately, with securing the airway if the Glasgow Coma Scale is <7, by intubating to protect the airway and positioning the head elevated at 30 degrees, as recommended by the EASL and AASLD 2, 9, 3, 5, 2
• Frequent neurological evaluations should be performed to monitor improvement in mental status, and ensure adequate bowel movements (2-3 per day), as recommended by the AASLD and EASL 6, 3
• Provide patient and caregiver education about medication adherence and recognition of early signs of recurrence, as recommended by the AASLD and EASL 6, 4

Special Considerations

• Common precipitants of hepatic encephalopathy include infections, gastrointestinal bleeding, electrolyte disorders, dehydration, and constipation, and rapid removal of blood from the GI tract using lactulose or mannitol via nasogastric tube is essential for patients with gastrointestinal bleeding to prevent worsening HE, as recommended by the AASLD and EASL 6, 9, 2
• Routine zinc supplementation is not recommended unless deficiency is demonstrated, as recommended by the AASLD and EASL 2
• Consider continuous kidney replacement therapy (CKRT), specifically high-dose continuous venovenous hemodialysis (CVVHD), for rapidly deteriorating neurological status with ammonia levels >150 μmol/l, as recommended by the EASL and AASLD 5, 2, 10